AR106231A1 - ANTI-CD19 HUMAN ANTIBODIES WITH HIGH AFFINITY - Google Patents
ANTI-CD19 HUMAN ANTIBODIES WITH HIGH AFFINITYInfo
- Publication number
- AR106231A1 AR106231A1 ARP160103010A ARP160103010A AR106231A1 AR 106231 A1 AR106231 A1 AR 106231A1 AR P160103010 A ARP160103010 A AR P160103010A AR P160103010 A ARP160103010 A AR P160103010A AR 106231 A1 AR106231 A1 AR 106231A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- antibody
- Prior art date
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicación 1: Un anticuerpo que se une específicamente a CD19 humano con una actividad más alta que un anticuerpo que comprende una cadena pesada variable que comprende una secuencia de aminoácidos de SEQ ID Nº 113 y una cadena ligera variable que comprende una secuencia de aminoácidos de SEQ ID Nº 114. Reivindicación 2: Un anticuerpo que se une específicamente a CD19 humano, en el que el anticuerpo comprende (a) CDR-L1 que comprende la secuencia de aminoácidos de SEQ ID Nº 43, (b) CDR-L2 que comprende la secuencia de aminoácidos de SEQ ID Nº 44, (c) CDR-L3 que comprende la secuencia de aminoácidos de SEQ ID Nº 45, (d) CDR-H1 que comprende la secuencia de aminoácidos de SEQ ID Nº 46, (e) CDR-H2 que comprende la secuencia de aminoácidos de SEQ ID Nº 47, y (f) CDR-H3 que comprende la secuencia de aminoácidos de SEQ ID Nº 48. Reivindicación 11: Un polinucleótido que codifica el anticuerpo según una cualquiera de las reivindicaciones 1 a 10. Reivindicación 15: Una formulación farmacéutica que comprende el anticuerpo según una cualquiera de las reivindicaciones 1 a 10 y un vehículo farmacéuticamente aceptable. Reivindicación 19: El anticuerpo según una cualquiera de las reivindicaciones 1 a 10 para su uso en el tratamiento de enfermedades autoinmunitarias, artritis reumatoide, lupus, psoriasis, o una enfermedad ósea. Reivindicación 20: Uso del anticuerpo según una cualquiera de las reivindicaciones 1 a 10 en la fabricación de un medicamento, particularmente un medicamento para el tratamiento de cáncer de linfocitos B.Claim 1: An antibody that specifically binds to human CD19 with a higher activity than an antibody comprising a variable heavy chain comprising an amino acid sequence of SEQ ID No. 113 and a variable light chain comprising an amino acid sequence of SEQ ID No. 114. Claim 2: An antibody that specifically binds to human CD19, wherein the antibody comprises (a) CDR-L1 comprising the amino acid sequence of SEQ ID No. 43, (b) CDR-L2 comprising the amino acid sequence of SEQ ID No. 44, (c) CDR-L3 comprising the amino acid sequence of SEQ ID No. 45, (d) CDR-H1 comprising the amino acid sequence of SEQ ID No. 46, (e) CDR- H2 comprising the amino acid sequence of SEQ ID No. 47, and (f) CDR-H3 comprising the amino acid sequence of SEQ ID No. 48. Claim 11: A polynucleotide encoding the antibody according to any one of claims 1 to 10 Claim 15: A pharmaceutical formulation comprising the antibody according to any one of claims 1 to 10 and a pharmaceutically acceptable carrier. Claim 19: The antibody according to any one of claims 1 to 10 for use in the treatment of autoimmune diseases, rheumatoid arthritis, lupus, psoriasis, or a bone disease. Claim 20: Use of the antibody according to any one of claims 1 to 10 in the manufacture of a medicament, particularly a medicament for the treatment of B lymphocyte cancer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15188262 | 2015-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR106231A1 true AR106231A1 (en) | 2017-12-27 |
Family
ID=54256656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160103010A AR106231A1 (en) | 2015-10-02 | 2016-09-30 | ANTI-CD19 HUMAN ANTIBODIES WITH HIGH AFFINITY |
Country Status (1)
Country | Link |
---|---|
AR (1) | AR106231A1 (en) |
-
2016
- 2016-09-30 AR ARP160103010A patent/AR106231A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181089A1 (en) | HUMAN ANTI-CD19 ANTIBODIES WITH HIGH AFFINITY | |
CL2019001926A1 (en) | Anti-tigit antibodies and antigen-binding fragments; pharmaceutical composition comprising them; polynenucleotide encoding said antibody; vector comprising them, host cell; method of producing said antibody or antigen-binding fragment thereof; and use in the treatment of cancer. (Divisional Application 310-2017). | |
AR111630A1 (en) | ANTI-SIRPa ANTIBODIES | |
AR109715A1 (en) | ANTI-CD27 ANTIBODIES | |
AR104213A1 (en) | ANTI-BODIES ANTI-CD38 AS THERAPEUTIC AGENTS | |
WO2015130416A9 (en) | Humanized rfb4 anti-cd22 antibody | |
AR080501A1 (en) | ANTIBODIES ANTI FACTOR ANTIGENIC DETERMINANT OF PROGRAMMED DEATH 1 (ANTI-PD1) | |
AR106184A1 (en) | PD-1 BINDING PROTEINS AND THEIR METHODS OF USE | |
AR106991A1 (en) | NEUTRALIZING ANTIBODIES OF THE HUMAN IMMUNODEFICIENCY VIRUS | |
AR105313A1 (en) | ANTI-BODY ANTI-CD137 THERAPEUTIC | |
PE20171654A1 (en) | COMPOSITIONS AND METHODS USED TO INCREASE IMMUNE RESPONSE AND IN CANCER THERAPY | |
AR110659A1 (en) | ANTI-NEUROPILIN ANTIGENS PROTEINS AND METHOD FOR USE | |
AR086044A1 (en) | ANTIBODIES THAT SPECIFICALLY JOIN A C-KIT EXTRACELLULAR DOMAIN AND USES OF THE SAME | |
AR102594A1 (en) | ANTI-IL-1b ANTIBODIES AND METHODS OF USE | |
PE20080214A1 (en) | ANTIBODY MOLECULES THAT JOIN HUMAN IL-17 | |
JP2018507220A5 (en) | ||
NZ705848A (en) | Anti-cd38 antibodies | |
PE20161221A1 (en) | IL-21 ANTIBODIES | |
JP2017518258A5 (en) | ||
AR109533A2 (en) | ANTI-FRACTALKINA ANTIBODIES OR A FRAGMENT OF UNION TO THE FKN OF THIS, COMPOSITIONS THAT INCLUDE IT AND METHODS TO TREAT INFLAMMATORY DISORDERS | |
PE20070998A1 (en) | ANTIBODY MOLECULES HAVING SPECIFICITY FOR IL-6-HUMAN | |
PE20212324A1 (en) | ANTIBODIES THAT RECOGNIZE TAU | |
AR096601A1 (en) | ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE | |
PE20170687A1 (en) | BINDING PROTEINS TO CD127 | |
PE20211605A1 (en) | ANTI-avß8 ANTIBODIES AND COMPOSITIONS AND USES OF THEM |